1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Israel Pharmaceuticals and Healthcare Report Q1 2017

Israel Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 118 pages

Includes 3 FREE quarterly updates


BMI View:

Israel will continue to be targeted by multinational drugmakers as a destination for innovative drug sales; however, their relative success will be limited by funding constraints towards the country's health services basket and the lack of transparency with new drug inclusions. An uptick in economic growth and an increase to government funding supports our moderate growth outlook for Israel's pharmaceuticals and healthcare sectors over the coming years.

Headline Expenditure Projections



- Pharmaceuticals: ILS7.82bn (USD2.01bn) in 2015 to ILS8.15bn (USD2.12bn) in 2016; +4.1% in local currency terms and +5.1% in US dollar terms. Forecast maintained from previous quarter.

- Healthcare: ILS89.43bn (USD23.02bn) in 2015 to ILS94.29bn (USD24.49bn) in 2016; +5.4% in local currency terms and +6.3% in US dollar terms. Forecast upgraded from previous quarter. Risk/Reward Index The Israeli pharmaceutical sector boasts a number of key qualities. These include a largely urbanised population and a significant pensionable proportion. Although intellectual property (IP) laws are currently being made more robust, we highlight long drug approval times as a hindrance to multinational drugmakers' ability to maximise their returns in the market. In our Pharmaceutical Risk/Reward Index (RRI) for Q117, the country scores 55.0 out of 100, maintaining its position as the third most attractive market for pharmaceutical investment in the Middle East and Africa (MEA), behind the United Arab Emirates (61.1) and Saudi Arabia (60.4), out of 31 countries analysed.

Table Of Contents

Israel Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Israel 2014-2020) 7
SWOT Analysis 9
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Israel 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Israel 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Israel 2012-2020) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Israel 2012-2020) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Israel 2012-2020) 30
Pharmaceutical Trade Forecast 31
Table: Pharmaceutical Trade Data And Forecasts (Israel 2014-2020) 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Israel 2014-2020) 33
Industry Risk/Reward Index 34
Middle East And Africa Risk/Reward Index - Q1 2017 34
Israel Risk/Reward Index 42
Rewards 42
Risks 42
Regulatory Review 44
Intellectual Property Issues 46
Pricing Regime 50
Table: Price Build-Up In The Israeli Pharmaceutical Market 51
Reimbursement Regime 51
Market Overview 55
Healthcare Sector 55
Table: Healthcare Resources (Israel 2010-2015) 62
Table: Healthcare Personnel (Israel 2010-2015) 62
Table: Healthcare Activity (Israel 2010-2015) 63
Research and Development 63
Table: Israel's RandD Legislation - Conditions For OCS Funding 66
Clinical Trials 66
Epidemiology 70
Competitive Landscape 73
Research-Based Industry 73
Table: Multinational Pharmaceutical Company Activity 77
Pharmaceutical Distribution 78
Pharmaceutical Retail Sector 78
Company Profile 80
Dexcel Pharma 80
Neopharm Group 83
Perrigo (Agis Industries) 87
Taro Pharmaceutical Industries 92
Teva Pharmaceutical Industries 97
Demographic Forecast 107
Table: Population Headline Indicators (Israel 1990-2025) 108
Table: Key Population Ratios (Israel 1990-2025) 109
Table: Urban/Rural Population and Life Expectancy (Israel 1990-2025) 109
Table: Population By Age Group (Israel 1990-2025) 110
Table: Population By Age Group % (Israel 1990-2025) 111
Glossary 112
Methodology 114
Pharmaceutical Expenditure Forecast Model 114
Healthcare Expenditure Forecast Model 114
Notes On Methodology 115
Risk/Reward Index Methodology 116
Index Overview 117
Table: Pharmaceutical Risk/Reward Index Indicators 117
Indicator Weightings 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.